Prospects for mucosal vaccine: shutting the door on SARS-CoV-2.
Hum Vaccin Immunother
; 16(12): 2921-2931, 2020 12 01.
Article
in English
| MEDLINE | ID: covidwho-759862
ABSTRACT
The sudden emergence of a highly transmissible and pathogenic coronavirus SARS-CoV-2 in December 2019 from China and its rapid global spread has posed an international health emergency. The rapid development of an effective vaccine is imperative to control the spread of SARS-CoV-2. A number of concurrent efforts to find an effective therapeutic agent or vaccine for COVID-19 (coronavirus disease 2019) are being undertaken globally. Oral and nasal mucosal surfaces serve as the primary portal of entry for pathogens like coronaviruses in the human body. As evidenced by studies on similar coronaviruses (SARS-CoV and MERS-CoV), mucosal vaccination can provide a safe and effective means for the induction of long-lasting systemic and mucosal immunity to confer protection against SARS-CoV-2. This article summarizes the approaches to an effective mucosal vaccine formulation which can be a rewarding approach to combat the unprecedented threat posed by this emerging global pandemic.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Vaccines
/
SARS-CoV-2
/
COVID-19
/
Nasal Mucosa
Type of study:
Observational study
Topics:
Vaccines
Limits:
Animals
/
Humans
Language:
English
Journal:
Hum Vaccin Immunother
Year:
2020
Document Type:
Article
Affiliation country:
21645515.2020.1805992
Similar
MEDLINE
...
LILACS
LIS